Innovative drug delivery technologies will play an increasingly important role in the future development of cancer therapy, and their application will be governed by trends in anticancer drug R&D. Decision Resources, Inc., announces the publication of Drug Delivery in Cancer: Technologies and Commercial Opportunities, a report that evaluates the numerous drug delivery strategies being developed in tandem with emerging therapeutics.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION)

Drug Delivery in Cancer: Technologies and Commercial Opportunities identifies the products already in Phase III trials and analyzes the strategic and commercial aspects of developing and marketing cancer drug delivery technologies. It offers invaluable market intelligence and strategic forecasts for pharmaceutical companies competing in this market. In addition, the report:

  -- Illustrates the relevance of genomics and pharmacogenomics to cancer      drug delivery.   -- Evaluates unmet needs in cancer drug delivery and the potential of      emerging technologies-including gene therapy, antisense technology, and      monoclonal antibodies-to meet these needs.   -- Estimates the market value of selected innovative technologies in      cancer drug delivery for 2000, 2005, and 2010 in the seven major      pharmaceutical markets (United States, France, Germany, Italy, Spain,      United Kingdom, and Japan.)   -- Profiles 17 companies developing innovative drug delivery technologies.  

Drug Delivery in Cancer: Technologies and Commercial Opportunities is available for $3,200.00. Contact Cindy Ohlman, 781.296.2521 (tel), 781.296.2525 (fax), or ohlman@dresources.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources/.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, 781-296-2521,
ohlman@dresources.com

Decision Resources to Publish Genomics and Drug Development: Impacts and Strategic Implications

View Now